Hemo Organic appoints V S S B & Associates as statutory auditor for five years
- Hemo Organic appoints M/s. V S S B & Associates as statutory auditor for five years
- The new term runs from the conclusion of the 34th AGM to the 39th AGM
- Outgoing auditors M/s M A A K & Associates completed their second term
- All three ordinary resolutions passed unanimously at the September 8 AGM

*this image is generated using AI for illustrative purposes only.
Hemo Organic Limited shareholders appointed M/s. V S S B & Associates, Chartered Accountants, as the company's statutory auditor for a five-year term during its 34th annual general meeting on September 8, 2026.
The appointment follows the completion of the second term by the outgoing auditors, M/s M A A K & Associates, Chartered Accountants (FRN: 135024W). The new auditors, based in Ahmedabad and holding FRN 121356W, will serve from the conclusion of the 34th AGM until the conclusion of the 39th AGM.
AGM Outcomes
The virtual meeting, held on September 8, 2026, saw unanimous approval for all three ordinary resolutions proposed by the board. Shareholders voted via electronic means to ratify the financial position for the period ending September 1, 2026, which served as the record date.
In addition to the auditor appointment, shareholders approved:
- Adoption of the annual audited financial statements and reports thereon.
- Appointment of Mr Murlidhar Joshi (DIN: 09819849) as a director retiring by rotation.
Jitendra Parmar of Jitendra Parmar & Associates served as the scrutinizer, submitting his report on September 9, 2026.
Voting Participation
A total of 4,825 shareholders were on the register as on the record date. Only 21 shareholders attended the meeting through video conferencing or other audio-video means. This included two promoter group members and 19 public shareholders. No shareholders attended in person or through proxy.
| Category | Shares Held | Votes Polled | Turnout % |
|---|---|---|---|
| Promoter Group | 583,940 | 583,940 | 100% |
| Public Non-Institutions | 2,881,960 | 6,715 | 0.233% |
| Total | 3,465,900 | 590,655 | 17.0419% |
Promoter entities held 583,940 shares and cast all their votes in favor of every resolution. Public non-institutional investors held 2,881,960 shares but polled only 6,715 votes, representing a turnout of 0.233%. No public institutional investors participated.
How might the appointment of M/s. V S S B & Associates influence Hemo Organic's financial reporting standards and regulatory compliance over the next five years?
What strategies could the board implement to address the critically low 0.233% turnout among public non-institutional shareholders in future AGMs?
Does the unanimous approval of resolutions despite minimal public participation raise any governance concerns regarding minority shareholder engagement?


























